Denali Advisors LLC Acquires 109,500 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Denali Advisors LLC lifted its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 41.1% in the 2nd quarter, Holdings Channel.com reports. The firm owned 375,965 shares of the company’s stock after buying an additional 109,500 shares during the quarter. Denali Advisors LLC’s holdings in Amphastar Pharmaceuticals were worth $7,587,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of AMPH. AQR Capital Management LLC raised its holdings in shares of Amphastar Pharmaceuticals by 82.0% during the first quarter. AQR Capital Management LLC now owns 53,638 shares of the company’s stock worth $1,555,000 after acquiring an additional 24,167 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Amphastar Pharmaceuticals by 2.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock valued at $652,000 after acquiring an additional 613 shares in the last quarter. Intech Investment Management LLC boosted its stake in Amphastar Pharmaceuticals by 43.0% in the 1st quarter. Intech Investment Management LLC now owns 60,289 shares of the company’s stock worth $1,748,000 after purchasing an additional 18,133 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in Amphastar Pharmaceuticals in the 2nd quarter worth $1,865,000. Finally, Invesco Ltd. increased its holdings in Amphastar Pharmaceuticals by 7.7% during the 2nd quarter. Invesco Ltd. now owns 386,971 shares of the company’s stock worth $8,885,000 after purchasing an additional 27,828 shares in the last quarter. 65.09% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on AMPH shares. Wells Fargo & Company lifted their price target on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, July 8th. Bank of America reiterated an “underperform” rating and set a $20.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Finally, Piper Sandler cut their target price on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. Six equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $22.50.

Insider Activity

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 8,180 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $22.48, for a total transaction of $183,886.40. Following the transaction, the chief financial officer owned 172,846 shares of the company’s stock, valued at $3,885,578.08. The trade was a 4.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard K. Prins sold 7,973 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $20.30, for a total value of $161,851.90. Following the transaction, the director directly owned 29,625 shares in the company, valued at $601,387.50. This trade represents a 21.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 29.60% of the company’s stock.

Amphastar Pharmaceuticals Stock Up 1.9%

Shares of AMPH stock opened at $21.74 on Thursday. The firm’s fifty day moving average price is $19.91 and its two-hundred day moving average price is $21.05. The company has a current ratio of 2.40, a quick ratio of 1.71 and a debt-to-equity ratio of 0.79. Amphastar Pharmaceuticals, Inc. has a 1 year low of $16.65 and a 1 year high of $31.26. The firm has a market capitalization of $924.82 million, a P/E ratio of 12.86, a PEG ratio of 4.51 and a beta of 0.89.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.29. The company had revenue of $183.90 million during the quarter, compared to the consensus estimate of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. On average, equities analysts predict that Amphastar Pharmaceuticals, Inc. will post 2.25 EPS for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.